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Specifically Targets Arthritic Cartilage
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Objective. To demonstrate that posttranslational
modification of type II collagen (CII) by reactive oxygen
species (ROS), which are known to be present in
inflamed arthritic joints, can give rise to epitopes spe-
cific to damaged cartilage in rheumatoid arthritis (RA)
and osteoarthritis (OA) and to establish a proof of
concept that antibodies specific to ROS-modified CII
can be used to target therapeutics specifically to in-
flamed arthritic joints.
Methods. We used a semisynthetic phage display
human antibody library to raise single-chain variable
fragments (scFv) specific to ROS-modified CII. The
specificity of anti–ROS-modified CII scFv to damaged
arthritic cartilage was assessed in vitro by immuno-
staining articular cartilage from RA and OA patients
and from normal controls. The in vivo targeting poten-
tial was tested using mice with antigen-induced arthri-
tis, in which localization of anti–ROS-modified CII scFv
in the joints was determined. The therapeutic effect of
anti–ROS-modified CII scFv fused to soluble murine
tumor necrosis factor receptor II–Fc fusion protein
(mTNFRII-Fc) was also investigated.
Results. The anti–ROS-modified CII scFv bound
to damaged arthritic cartilage from patients with RA
and OA but not to normal preserved cartilage. When
systemically administered to arthritic mice, the anti–
ROS-modified CII accumulated selectively at the in-
flamed joints. Importantly, when fused to mTNFRII-Fc,
it significantly reduced inflammation in arthritic mice,
as compared with the effects of mTNFRII-Fc alone or of
mTNFRII-Fc fused to an irrelevant scFv.
Conclusion. Our findings indicate that biologic
therapeutics can be targeted specifically to arthritic
joints and suggest a new approach for the development
of novel treatments of arthritis.
Cartilage destruction is a key pathologic feature
of joint disorders such as rheumatoid arthritis (RA) and
osteoarthritis (OA), conditions that represent a pressing
social and economic burden, especially in view of an
increasingly aging population. Arthritis is often poly-
articular and therefore requires systemic administration
of therapeutic agents. Systemic treatment with disease-
modifying antirheumatic drugs (DMARDs) is associated
with side effects, since such treatment does not deliver
pharmacologically active molecules solely to the site of
disease activity in the joints.
The problem remains unresolved with biologic
DMARDs, including the tumor necrosis factor 
(TNF)–blocking class of proteins, which have been
established as a standard in the treatment of RA in
patients whose disease has failed to respond to conven-
tional DMARDs (1). However, the financial strain
placed on healthcare systems by the prescription of
high-priced biologic agents is a major burden (2). In
addition, because of the generalized immunosuppres-
sion in patients receiving biologic agents, there are
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safety issues due to the high risk of developing infections
(3). Also, a significant number of patients do not re-
spond to anti-TNF therapy. Therapeutic options for
these patients include increasing the dose, switching to
an alternative TNF antagonist, or switching to a biologic
drug of a different class, such as rituximab, abatacept,
(4) and more recently, tocilizumab (5). Regardless of
whether TNF, interleukin-6 (IL-6), or CD20 blockade
therapy is used, there is an unmet need for the develop-
ment of novel therapies with improved efficacy and
substantially reduced side effects.
In RA, inflammatory cells infiltrate the inflamed
synovial membrane (6), producing high levels of inflam-
matory cytokines, such as TNF and IL-1 (7), which in
turn lead to the production of matrix metalloproteinases
(MMPs), which are responsible for the destruction of
cartilage (8). Moreover, the influx of infiltrating leuko-
cytes consumes increased amounts of oxygen, resulting
in the overproduction of O2
. radical and leading to the
generation of derivative oxidants such as H2O2,
.OH,
and HOCl (9–12). An excess of nitric oxide, another key
proinflammatory mediator (12), reacts with O2
. to form
ONOO. Although synovial inflammation in OA is not
as extensive as in RA, similar mediators of inflammation
are produced either by chondrocytes (13) or by infiltrat-
ing B and T lymphocytes (14). As in RA, oxidative stress
may also play a major role in the development of OA.
Furthermore, the link between OA and aging might be
due to excessive levels of reactive oxygen species (ROS)
that tip the balance of anabolic and catabolic events,
with a resulting loss of homeostasis. Moreover, in OA as
well as in RA, cartilage degradation is associated with
nonenzymatic glycation, which generates advanced gly-
cation end products (AGEs). A hallmark of AGEs is
pentosidine, the levels of which are increased in RA and
OA despite the absence of hyperglycemia (15).
We studied the immunopathologic events follow-
ing ROS-mediated modification of type II collagen
(CII), a main and specific component of the cartilage
extracellular matrix and a known autoantigen in RA. We
have previously reported a substantial increase in bind-
ing of RA sera to ROS-modified CII, as compared with
binding to native unmodified CII (16). In the current
study, assuming that ROS-modified CII is present only
in the inflamed joints and using a phage display human
antibody library, we identified a human single-chain
variable fragment (scFv) that binds specifically to ROS-
modified CII. Indeed, the anti–ROS-modified CII scFv,
1-11E, was found to bind specifically to damaged carti-
lage characteristic of RA and OA, but not normal
articular cartilage. Importantly, using a mouse model of
monarticular antigen-induced arthritis (AIA), we pro-
vide herein a proof of concept that the anti–ROS-
modified CII scFv can be used to target therapeutic
agents exclusively to damaged cartilage in arthritic joints.
MATERIALS AND METHODS
Development of anti–modified CII scFv from the
phage display library. CII was prepared from bovine cartilage
(17) and subsequently exposed to reactive oxygen–generating
systems. Briefly, CII was modified with .OH, HOCl, ONOO,
or ribose by overnight incubation at 37°C, as described previ-
ously (16). To select for the scFv specific to ROS-modified CII,
we used a human semisynthetic scFv library (18). Selection was
performed as described previously (online at http://www.
geneservice.co.uk/products/proteomic/datasheets/tomlinsonIJ.
pdf), with some modifications. To select for phage binding
specifically to ROS-modified CII and not to native CII, 3
rounds of subtractive selection were performed using native
CII for subtraction. Soluble scFv were obtained from an
infected, nonsuppressor Escherichia coli HB2151 bacterial
strain, as described previously (19). To select for a specific scFv
to hen egg lysozyme (HEL), which served as a control, we used
a standard protocol.
Samples of human RA, OA, and normal cartilage.
Human RA cartilage samples (provided by Professor C. Mon-
tecucco, Universita` degli Studi di Pavia, Pavia, Italy) were
obtained from 2 patients who were diagnosed according to the
American College of Rheumatology (formerly, the American
Rheumatism Association) revised criteria for RA (20) and who
were undergoing total knee joint replacement. At the time of
sample collection, the patients were 52 and 47 years old, with
a disease duration of 13 and 15 years, respectively. Both
patients had been treated with steroids and DMARDs, such as
methotrexate and sulfasalazine. OA cartilage samples (also
provided by Professor C. Montecucco) were obtained from 3
additional patients undergoing prosthetic knee replacement.
Normal cartilage was obtained postmortem and exhibited no
histologic evidence of joint pathology. All samples were col-
lected in accordance with institutional ethics policies and
regulations (Istituto Ricerca Cura Carattere Scientifico Foun-
dation Policlinico San Matteo, Pavia, Italy).
Immunohistochemistry. Safranin O staining was per-
formed according to standard protocols (21). For immuno-
staining, sections 5 m thick were deparaffinized and hydrated
according to standard protocols. After endogenous peroxidase
quenching in 3% H2O2 for 15 minutes, antigen retrieval was
performed by incubating slides with 3 mg/ml pepsin (Zymed,
Chandlers Ford, UK) for 45 minutes at 37°C. Using a blocking
solution of 0.5% bovine serum albumin (BSA) in phosphate
buffered saline (PBS), sections were incubated overnight at
4°C with either the selected scFv (10 g/ml) or control
commercial mouse anti-CII antibodies (1:1,000 dilution;
Chemicon International, Chandlers Ford, UK). Mouse anti–
Myc-Tag antibodies were used to bind to the Myc-Tag incor-
porated at the carboxy-terminal end of the scFv (1:200 dilu-
tion; Santa Cruz Biotechnology, Wembley, UK), which was
followed by incubation with a goat anti-mouse biotinylated
antibody, using a Vectastain PK-6102 kit according to the
instructions of the manufacturer (Vector, Peterborough, UK).
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Immunostaining with the control commercial mouse antibod-
ies (1:1,000 dilution; Millipore, Watford, UK) was probed with
a goat anti-mouse antibody as above. Diaminobenzidine sub-
strate was used as peroxidase substrate (Dako, Ely, UK).
Sections were counterstained with hematoxylin and mounted
with DPX (BDH, London, UK). Immunohistochemical analy-
sis of the mouse cartilage sections was performed following the
same procedure used for the human cartilage specimens,
except that a rat anti–Myc-Tag followed by horseradish perox-
idase (HRP)–conjugated anti-rat antibodies were used, ac-
cording to the instructions of the manufacturer (Dako).
Mouse models of arthritis. We used mice with AIA as
a model for inflamed arthritis (22). To obtain an AIA model of
chronic arthritis, animals were rechallenged with methylated
BSA (mBSA) 1 month after the first challenge with mBSA,
which was injected into either inflamed knees or paws as
described previously (23). C57BL/6 mice subjected to knee
injury were next used as a posttraumatic OA model. Knee
injury in the patellar groove was induced by microsurgery, as
described previously (24). All animal procedures were per-
formed according to institutional guidelines approved by the
Home Office.
Imaging accumulation of fluorescence-labeled 1-11E
in the arthritic paw. An Alexa Fluor 680 protein labeling kit
(Invitrogen, Paisley, UK) was used to label 1-11E and control
anti-HEL, according to the manufacturer’s instructions. Mice
with AIA were rechallenged with mBSA 3 days before intra-
venous injection of an equal amount of fluorescent scFv (5 g
and 6.7 g for 1-11E and anti-HEL, respectively). At various
time points, the localization of the scFv was determined by
placing mice anesthetized with isoflurane into an IVIS 100
Series imager (Caliper Life Sciences, Hopkinton, MA). High-
resolution images were obtained by 2-second exposure using
the Cy5 setting in the Living Image software (Caliper Life
Sciences). In addition, the images were corrected for autofluo-
rescence of the mice and the imaging box.
Fusing 1-11E and anti-HEL scFv to murine tumor
necrosis factor receptor II–Fc fusion protein (mTNFRII-Fc).
Polymerase chain reaction–amplified mTNFRII-Fc was cloned
into pFastBac1.AH, which was created from pFastBac1 (In-
vitrogen), and fused to 1-11E or control anti-HEL scFv via the
MMP-1 cleavage site (25). The construct was transformed into
DH10Bac competent cells to generate bacmid vectors, fol-
lowed by transfection of bacmid DNA into Sf9 insect cells
using Cellfectin, according to the manufacturer’s instructions
Figure 1. Binding of 1-11E to reactive oxygen species (ROS)–
modified type II collagen (CII). A, An enzyme-linked immunosorbent
assay (ELISA) to test binding of the anti–ROS-modified CII single-
chain variable fragment (scFv) 1-11E to native and modified CII was
performed as described previously (43). Briefly, a microtiter plate was
coated with native CII or CII modified by glycation, HOCl, .OH, or
ONOO. After blocking and incubation with 1-11E, mouse anti–Myc-
Tag antibodies were added, followed by horseradish peroxidase
(HRP)–conjugated anti-mouse antibodies, to probe bound scFv. In the
ELISA, 1-11E bound to most types of modified CII (bars 2–5) but did
not bind to native CII (bar 1). B, Western blotting was performed as
described previously (16). Briefly, modified and native bovine CII were
run on a sodium dodecyl sulfate gel under reducing conditions and
then blotted onto a nitrocellulose membrane. After blocking, mem-
branes were incubated with 1-11E, then with mouse anti–Myc-Tag, and
then with HRP-conjugated anti-mouse antibodies. Binding of 1-11E to
a range of CII -chain fragments below 100 kd, as well as to aggregates
with high molecular weight, was observed. Numbered horizontal bars
represent the position of molecular weight markers, in kd. Lanes 1–5
represent native CII and CII modified by glycation, HOCl, .OH, or
ONOO, respectively. OD  optical density.
Figure 2. Binding of 1-11E to cartilage in patients with rheumatoid
arthritis (RA) and osteoarthritis (OA). Antibody 1-11E diffusely
stained RA cartilage in all layers (brown). A, Staining of the RA
specimen in the superficial area and the middle zone was stronger than
that in the deep zone. B, Staining of the RA specimen with Safranin O
was weak and localized mainly in the deep zone (red). C, Staining of an
OA cartilage sample with extensive erosions and marked surface
damage, including the formation of fragments discrete from the parent
cartilage, was strong in the most severely damaged area. D, Staining
with 1-11E colocalized with an area of weak Safranin O staining in a
parallel nonconsecutive OA cartilage section. E and F, Antibody 1-11E
staining of cartilage from a patient with mild OA with typical fissuring
of the surface of the upper cartilage appeared as a territorial “halo”
around the chondrocytes (E), while staining with Safranin O was
strong (F). G–I, Staining of the subchondral bone was not observed in
any of the samples tested. No staining with 1-11E was detected in
histologically normal cartilage (G), which also stained normally with a
commercial anti–type II collagen monoclonal antibody (H) and with
Safranin O (I). Bars in A and B  5,000 m; bars in C–H  2,000 m;
bar in I  500 m.
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(Invitrogen). Amplified virus was used to infect High Five
insect cells for 72 hours for expression of the recombinant
protein. Expression was analyzed by Western blotting using
mouse anti–Tetra-His antibody (1:500 dilution; Qiagen, Craw-
ley, UK) and HRP-conjugated anti-mouse antibodies (1:1,000
dilution; Sigma, Dorset, UK). Protein purification was per-
formed using a nickel chelate column purification kit, accord-
ing to the manufacturer’s instructions (Qiagen). Overnight
digestion of MMP-1 at 37°C was performed as described
previously (25).
Targeted delivery of TNFRII to arthritic joints.
C57BL/6 mice with chronic-phase AIA were used. Mice were
rechallenged with mBSA by injecting 50 g mBSA in PBS into
the knee of each animal 1 day before treatment. On days 1 and
3 after mBSA rechallenge, animals were injected intraperito-
neally with 20 g of 1-11E/mTNFRII-Fc or control HEL/
mTNFRII-Fc, as described previously (26). When control
mTNFRII-Fc (lacking the scFv, and thus with a molecular
weight50 kd lower) was used, we injected 13.33 g of protein
so that the molar concentrations of the various recombinant
proteins were equivalent. Swelling of the knee was measured
daily using calipers.
Statistical analysis. Statistical analyses were under-
taken using 1-tailed unpaired Mann-Whitney U test or
repeated-measures analysis of variance, as applicable. An 
value of 0.05 was used as the threshold for significance.
RESULTS
Generation of anti–modified CII scFv raised by
the phage display human antibody library. After 3
rounds of subtractive selection, 42 phage clones with
unique sequences specific to ROS-modified CII were
selected. From among the most ROS-modified CII–
specific clones that had no background binding to native
CII, clone 1-11E had the best expression yield and
became the focus of further studies. Most importantly,
clone 1-11E exhibited binding to all forms of ROS-
modified CII (Figure 1A). These findings suggested a
capacity for identifying a wide range of potential oxida-
tive modifications of CII by different ROS present
during acute and chronic inflammation in arthritis. In
addition, 1-11E did not bind to BSA modified by ROS
(data not shown). Western blot analysis revealed that
1-11E bound to a range of fragments from the CII
-chain below 100 kd, as well as to aggregates of high
molecular weight that result from the exposure of CII to
ROS (16). Moreover, as we demonstrated previously for
established RA sera (16), 1-11E also bound to the
electrophoretic band that corresponds to the intact
native CII -chain polypeptide, although in an enzyme-
linked immunosorbent assay, 1-11E did not bind to
native CII (Figure 1B).
Specific binding of 1-11E to damaged human
articular cartilage. The cartilage extracellular matrix is a
complex structure where several molecules interact to
form structural and functional units. Selected in vitro
against purified ROS-modified CII, 1-11E may not
recognize the tertiary and quaternary structure of colla-
gens in the intact tissue. To determine binding specificity
in the intact tissue, we tested the capacity of 1-11E to
bind to ROS-modified CII within the cartilage matrix of
arthritic cartilage from patients with RA, where inflam-
mation is extensive, compared with that in OA, where
inflammation is milder. As shown in Figure 2A, the
staining of RA cartilage by 1-11E displayed a diffuse
pattern in all layers of the section, reflecting the pres-
ence of high levels of ROS across the cartilage, which
Figure 3. Binding of 1-11E to cartilage from mice with experimental inflammatory arthritis and posttraumatic osteoarthritis (OA). A and B,
Inflamed cartilage was uniformly and strongly stained with 1-11E (A), while no staining was observed using irrelevant anti–hen egg lysozyme
(anti-HEL) single-chain variable fragment (scFv) (B). C, Antibody 1-11E did not stain control uninflamed cartilage. D, Strong pericellular staining
with 1-11E was observed in the damaged area of cartilage from mice with knee injury that developed posttraumatic OA. E, No binding was observed
using control anti-HEL scFv. Bars  100 m.
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may result from the high influx of reactive immune cells
into the joint. Staining in the deep zone, however, was
weak. This staining pattern was opposite that of Safranin
O, which showed strong staining in the deep zone, but
weak or absent staining on the articular surface and in
the middle zone (Figure 2B).
We next tested the binding of 1-11E to damaged
cartilage from patients with OA, in whom the features of
inflammation are less marked than those in patients with
RA. Accordingly, in OA cartilage, strong staining was
associated with cartilage areas exhibiting features of
active OA, including altered Safranin O staining, cell
clustering, and clefts. In an OA cartilage specimen with
extensive erosions, strong staining was observed in the
regions of severely damaged cartilage, with typical
strong staining in areas of the fragmented cartilage
(Figure 2C). Staining with Safranin O showed a pattern
opposite that of 1-11E, with little overlap between the
two (Figure 2D). In a specimen from a patient with mild
OA with typical fissuring of the upper surface of the
cartilage, immunostaining with 1-11E was specific to the
damaged superficial layer, and there was strong staining
as a territorial “halo” around the chondrocyte clusters
(Figure 2E). This specimen stained strongly with Safra-
nin O, as shown in Figure 2F, but exhibited weaker
staining in the more severely damaged area (e.g., the
cleft).
In all specimens, no staining with 1-11E was
observed in the subchondral bone. Moreover, no stain-
ing with 1-11E was observed in histologically normal
human cartilage (Figure 2G). However, strong and
specific staining was observed when commercial anti-CII
antibodies were used (Figure 2H), confirming that the
lack of staining with 1-11E was not due to a lack of
accessibility of CII in the intact undamaged cartilage.
Hence, a canonical staining pattern with Safranin O was
observed (Figure 2I).
Staining of cartilage from mice with experimen-
tal arthritis. To validate the findings in human RA
cartilage sections, we studied cartilage from mice with
experimental inflammatory arthritis (22). As seen in
Figure 3A, cartilage from inflamed paws was strongly
Figure 4. Selective accumulation of 1-11E in the inflamed paw. Mice with antigen-induced arthritis and similar degrees of paw
swelling were injected intravenously with Alexa Fluor 680–labeled 1-11E and with control anti–hen egg lysozyme (anti-HEL
[C7]) (n  3 per group). Single-chain variable fragment (scFv) localization analysis was performed using ImageJ software (NIH
Image, National Institutes of Health, Bethesda, MD; online at http://rsbweb.nih.gov/ij/); the RGB Split and Image Calculator
functions in ImageJ were used to subtract background from signal. The localization index is the product of the area and the mean
pixel density, corrected for scale bar variations between images (Excel; Microsoft, Redmond, WA). A, Greater accumulation of
1-11E was observed in inflamed paws than in uninflamed paws after 3 hours. Control anti-HEL scFv exhibited no specific
accumulation, and the signal was reduced down to a constant level throughout the experiment. At 1 hour, the level of localized
fluorescence-labeled 1-11E in inflamed paws was 3 times lower than the level of fluorescence-labeled anti-HEL (P  0.05) in
inflamed paws. At 3 hours, however, the level of localized fluorescence-labeled 1-11E was 2 times higher than the level of
fluorescence-labeled anti-HEL in inflamed paws (P 0.05). Values are the mean SD. B and C, Scans of mice with an inflamed
left paw (B) or knee (C) that were injected with fluorescence-labeled 1-11E revealed specific accumulation of 1-11E in the
inflamed tissue.
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and uniformly stained with 1-11E but not with the
irrelevant anti-HEL scFv (Figure 3B). In addition, 1-11E
did not stain uninflamed preserved mouse cartilage
(Figure 3C).
OA cartilage was obtained from C57BL/6 mice
with knee injuries, which repair poorly and thus develop
features of posttraumatic OA (24). Clear pericellular
staining was observed in the damaged area stained with
1-11E (Figure 3D), while no staining was detected when
staining with the control anti-HEL scFv (Figure 3E).
Selective accumulation of 1-11E at the site of the
inflamed paw. Next, we established whether anti–ROS-
modified CII scFv would accumulate in vivo in the
inflamed joint versus uninflamed joints following sys-
temic administration during the chronic phase of the
AIA model. Upon challenging animals with mBSA 3
weeks after the first stimulation, mice with a similar
degree of paw swelling (n  3) were injected intrave-
nously with 1-11E labeled using an Alexa Fluor 680
protein labeling kit and with control anti-HEL. As
shown in Figure 4A, by imaging the mice, we observed a
greater accumulation of 1-11E in the inflamed paw, with
maximum accumulation of 1-11E observed 3 hours after
injection (P  0.001). In contrast, irrelevant anti-HEL
scFv showed no specific accumulation. The input fluo-
rescence signal of anti-HEL scFv in the inflamed paw
was reduced 40% at 3 hours and maintained this
approximate level for the remainder of the experiment
(Figure 4A). Moreover, accumulation of 1-11E was
specific to the inflamed paw (Figure 4B) or knee (Figure
4C), with very low or no background localization in the
uninflamed joints or other cartilaginous organs.
Treatment of mice with AIA with an 1-11E and
mTNFRII-Fc fusion protein product. To investigate the
ability of 1-11E to deliver soluble TNFRII to the ar-
thritic joint, 1-11E was fused to mTNFRII-Fc. In addi-
tion, an MMP cleavage site was inserted to assure the
release of mTNFRII-Fc at the site of the inflammation
(25) (Figure 5A). Western blot analysis revealed the
fusion protein product with the expected 75 kd molec-
ular weight band, which reflects the total of the pre-
dicted 50 kd mTNFRII-Fc combined with the 25 kd
scFv. Incubation of the fusion protein with recombinant
MMP-1 resulted in detection of a band in the region of
25 kd corresponding to the scFv cleaved from
mTNFRII-Fc (Figure 5B). The biologic activity of
mTNFRII-Fc was then tested by determining its ability
to inhibit in vitro the TNF-mediated activation of a
reporter luciferase gene driven by an NF-B promoter.
From this, it was concluded that the potency of the
fusion of soluble 1-11E with mTNFRII-Fc as an inhibi-
tor of TNF was as strong as soluble TNFRII-Fc alone
(Figure 5C).
The therapeutic potency of the fusion of 1-11E
and mTNFRII-Fc was tested in experimental arthritis
using the chronic AIA protocol. After rechallenge with
Figure 5. Fusion of 1-11E to soluble murine tumor necrosis factor receptor II–Fc fusion protein (mTNFRII-Fc). A, Schematic representation of the
1-11E/mTNFRII-Fc construct containing a matrix metalloproteinase (MMP) cleavage site between 1-11E and mTNFRII-Fc. Murine TNFRII-Fc
was amplified with forward primer A (5-GCTAAGCTTATGGCGCCCGCCGCCCTC) and reverse primer B (5-CTTGAA-
TTCTTTACCCAGAGACCGGGA). After digestion, the polymerase chain reaction (PCR)–amplified fragment was cloned into the Hind III–Eco
RI sites of pFastBac1.AH, which was created from pFastBac1 (Invitrogen) containing an MMP-1 cleavage site cloned between Eco RI and Not I.
Antibody 1-11E or control anti–hen egg lysozyme (anti-HEL) single-chain variable fragment (scFv) was amplified with forward primer C
(5-CAGGCGGCCGCAATGGCCGAGGTGCAGCTG-3) and reverse primer D (5-CTTGGGCCCTCAATGGTGGTGGTGATGG-
TGTCTAGACCGTTTGATTTCCACCTT-3) to amplify the scFv and to include a His-Tag between Xba I and Apa I. The PCR-amplified fragment
was then digested and cloned into pFastBac1.AH digested with Not I and Apa I. The fusion protein was expressed using the baculovirus expression
system. B, Western blot analysis of the fusion protein product with the expected molecular weight band of 75 kd, which was reduced to 25 kd after
cleavage with MMP-1, corresponding to the scFv detected by the anti–His-Tag. C, Measurement of the activity of the 1-11E/mTNFRII-Fc fusion
protein. The activity of the 1-11E/mTNFRII-Fc fusion protein was similar to that observed with mTNFRII-Fc alone, as measured by inhibition of
TNF-mediated induction of the NF-B promoter–driven luciferase reporter gene (luc) in HeLa 57A cells. Values are the mean.
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mBSA, mice with similar degrees of knee swelling were
selected for treatment. Intraperitoneal injection of
1-11E fused with mTNFRII-Fc on day 1 and day 3 after
rechallenge significantly reduced knee swelling com-
pared with the administration of either control anti-
HEL fused with mTNFRII-Fc (P  0.001) or control
mTNFRII-Fc alone (P  0.01) (Figure 6).
DISCUSSION
The advent of biologic DMARDs such as anti-
TNF has revolutionized the treatment of RA. How-
ever, systemic administration does not deliver pharma-
cologically active molecules solely to arthritic joints and
therefore could contribute to side effects. Targeted
therapy would concentrate the bioactive molecules
within the damaged joints and, thus, could increase
potency while minimizing side effects. However, a major
problem with applying targeted therapies in arthritis has
been the identification of specific markers of inflamed
joint tissue to deliver the antiinflammatory agent. An
scFv specific to a marker of angiogenesis was previously
used to target cytokines in mice with collagen-induced
arthritis (CIA) (27). An angiogenic marker, however, is
not specific to arthritic joint tissue, and so the problem
has remained unresolved. We hypothesized that CII is
the best candidate for targeting therapy to the joint
because it is specific to cartilage. Nevertheless, there is a
need to find a way to target the drugs solely to the
damaged joints, since CII is a major component of both
healthy and arthritic joints. To allow targeting to a
damaged joint independently of the etiology of the
damage, we hypothesized that CII modified by ROS,
which is present only in the damaged arthritic joint,
would be a suitable target.
Using a phage display human antibody library, we
developed a panel of human scFv that bind only to CII
modified in vitro by known reactive oxidants in RA
(28,29). Out of many clones tested, clone 1-11E bound
to all forms of ROS-modified CII and had the capacity
to recognize a wide range of potential oxidative modifi-
cations of CII by different ROS present during acute and
chronic inflammation. Similar to the findings in serum
samples from patients with established RA, 1-11E bound
to a range of fragmented and aggregated CII bands as
well as to native CII, as determined by Western blotting
(16,28–32). The binding of 1-11E to native CII was
probably 1-11E binding to denatured epitopes of native
CII, which result from the strong denaturing conditions
in sodium dodecyl sulfate gels. In addition, some CII
oxidation could occur during gel electrophoresis.
Most importantly, 1-11E bound only to arthritic
cartilage and not to normal intact cartilage. We analyzed
the binding of 1-11E to damaged cartilage in 2 types of
arthritis, RA and OA. The staining pattern observed in
RA cartilage was fundamentally different from that
observed in OA cartilage, reflecting the basic difference
between RA and OA pathogenesis. Strong, diffused
staining of RA cartilage with 1-11E was observed. Stain-
ing of the deep zone, however, was very weak. Interest-
ingly, staining with Safranin O (which stains sulfated,
negatively charged glycosaminoglycans and is thus di-
rectly proportional to the intact proteoglycan content)
was detected mainly in the deep zone of the RA
specimen. This reverse pattern may reflect a high influx
of infiltrating immune cells within the synovial mem-
Figure 6. Superior therapeutic effect of 1-11E/murine tumor necrosis
factor receptor II–Fc fusion protein (mTNFRII-Fc) in the antigen-
induced arthritis (AIA) model. We used mice with AIA during the
chronic phase of disease that were rechallenged with methylated
bovine serum albumin (mBSA), followed by injection of therapeutic
protein on day 1 and day 3 (n  8 for the 1-11E/mTNFRII-Fc and the
hen egg lysozyme [HEL]/mTNFRII-Fc treatment groups; n 7 for the
mTNFRII-Fc and phosphate buffered saline [PBS] control groups).
Reduction of swelling of inflamed knees was accelerated in mice in the
1-11E/mTNFRII-Fc fusion group as compared with the control anti-
HEL/mTNFRII-Fc and mTNFRII-Fc groups (P 0.0008 by repeated-
measures analysis of variance). P values for the post hoc test were
calculated using the Newman-Keuls multiple comparison test: for
1-11E/mTNFRII-Fc versus HEL/mTNFRII-Fc, P  0.001; for 1-11E/
mTNFRII-Fc versus mTNFRII-Fc, P  0.01; and for HEL/
mTNFRII-Fc versus mTNFRII-Fc, P  0.05. These results indicate
that 1-11E specifically accelerates the reduction of knee swelling.
Values are the mean and SD.
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brane, producing high levels of ROS that mostly modify
both the superficial layers, which have direct contact
with the inflamed synovial fluid and the synovial mem-
brane pannus, and the middle zone, which is more
accessible than the deep zone. When cartilage from mice
with AIA, an experimental model of inflamed arthritis,
was stained with 1-11E, it exhibited strong diffused
staining similar to that observed in human RA cartilage.
Synovial inflammation in OA is not as extensive
as in RA, and mediators of inflammation appear to be
produced mainly by chondrocytes (13,15). The inflam-
matory and catabolic events leading to cartilage loss in
RA and OA are different entities and have different
origins. In RA, mediators of inflammation originate
from the inflamed synovial membrane and are extrinsic
to cartilage, whereas in OA, they originate from the
chondrocytes themselves. This may explain the strikingly
different patterns we observed with 1-11E staining,
which was diffuse in RA samples and pericellular or
territorial in OA samples. Although 1-11E stained de-
graded OA cartilage, it is interesting that 1-11E staining
did not always correlate with certain features of OA,
such as decreased staining with Safranin O, structural
features (clefts), and cellular features (clusters and
hypocellularity). Such features reflect the cumulative
damage to cartilage and the final balance between
degradation and anabolism, whereas staining with 1-11E
reflects a snapshot of local ROS-mediated collagen
modification/inflammation.
For example, in the cartilage sample from a
patient with mild OA, the territorial and pericellular
1-11E staining around the chondrocyte clusters implies
that there is enhanced inflammatory activity and high
levels of ROS-modified CII, overlapping with strong
staining with Safranin O, which may reflect enhanced
anabolic activity (33). This may be an important feature
of 1-11E staining in diseases such as OA, which have
alternating periods of progression and quiescence or
even partial recovery (34). Such a feature of 1-11E may
also help to identify patients in whom cartilage degra-
dation is predominantly driven by inflammation rather
than by a lack of anabolic activity. Interestingly, in the
cartilage sections from mice with experimental posttrau-
matic OA, we observed pericellular staining with 1-11E,
which was similar to the staining with antibodies specific
to neoepitopes generated by MMP-cleaved CII, as de-
scribed previously (24). A previous correlation between
oxidation and OA cartilage degradation was demon-
strated by Yudoh et al (35), who observed strong
staining for nitrotyrosine and a low antioxidant capacity
in the degenerative region of OA cartilage compared
with the intact region from the same sample. In conclu-
sion, the different staining pattern produced by 1-11E in
RA cartilage versus OA cartilage may reflect the differ-
ences between RA, in which inflammation is driven by
synovitis, and OA, in which inflammation is predomi-
nantly driven by chondrocytes (13,15).
The inflamed joint and cartilage represent a
complex structure, and there was a possibility that 1-11E
would not be able to access ROS-modified CII in the
inflamed joint in vivo. After intravenous injection of
1-11E into mice with AIA, we observed a specific
accumulation of 1-11E in the inflamed paw, with maxi-
mum accumulation 3 hours after the injection, consistent
with the known 2-hour half-life of the scFv (36). In
contrast, irrelevant anti-HEL scFv exhibited no specific
accumulation, but rather, it exhibited nonspecific local-
ization due to increased extravasation into the inflamed
joint versus the uninflamed joint.
The potential of 1-11E to facilitate the targeting
of therapeutics specifically to the inflamed joint was
assessed by fusing 1-11E to soluble mTNFRII as a proof
of concept. A therapeutic effect was observed for 1-11E/
mTNFRII-Fc, since it accelerated the reduction of in-
flamed knee swelling, compared with the effects of
irrelevant anti-HEL/mTNFRII-Fc and control
mTNFRII-Fc. We have therefore clearly demonstrated
for the first time specific targeting of a therapeutic agent
to inflamed joints by using damaged, cartilage-specific
epitopes present specifically in the inflamed joints. Al-
though CII is a major component of both healthy and
arthritic joints, an antibody specific to ROS-modified
CII, 1-11E, targeted a therapeutic moiety (mTNFRII-
Fc) solely to the damaged arthritic joint, because ROS-
modified CII is present only in inflamed joints. Inter-
estingly, while 1-11E is cleared from the circulation in
3–6 hours, the therapeutic effect of 1-11E/mTNFRII-Fc
lasted for a few days. This is consistent with previous
observations in mice with experimental CIA that were
injected with mTNFR-Fc (1,37,38). The longer thera-
peutic effect reflects subsequent changes in downstream
biologic events that are hierarchically controlled by
TNF (1) and are therefore blocked as a result of TNF
blockade. In addition, we anticipate that the longer
serum half-life of anti–ROS-modified CII/mTNFRII-Fc
(molecular weight 150 kd versus 27 kd for the
anti–ROS-modified CII scFv) may have contributed to
longer efficacy (39).
We believe that this development, which would
allow for the delivery of drugs specifically to inflamed
joints, has the potential to revolutionize the treatment of
RA, although further studies are needed to optimize the
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pharmacokinetics of this scFv. The development may
also have a significant impact on the treatment of OA,
which has lagged well behind that of RA (40,41). Once
optimized for the clinical setting (and depending on the
size of the payload drug), 1-11E, as an scFv, offers a
small drug-delivery system with increased tissue pene-
tration, short systemic half-life, and renal clearance in
vivo (39). It has recently been demonstrated that the
anti-TNF scFv, ESBA 105, had superior synovial and
cartilage penetration over intact infliximab, using a
short-term monarthritis model in which rats were in-
jected intraarticularly with an anti-TNF scFv (42).
Antibody 1-11E offers an advantage over the anti-TNF
scFv, since it will specifically deliver the anti-TNF ther-
apy to the affected joint, even when applied systemically,
without the need for intraarticular injection. In fact,
once optimized for clinical use, 1-11E could have a
dramatic impact on treatment efficacy and modality. A
drug could be injected using the standard systemic
administration, such as intravenous injection, but with a
significant increase in potency and with minimized side
effects.
In summary, regardless of the disease pathology,
whether OA or RA, 1-11E has the potential for targeting
anti-TNF, other inflammatory cytokine blockers, or
cartilage regenerating factors specifically to diseased
tissues.
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